Cisplatin plus 5-fluorouracil is regarded as standard neoadjuvant chemotherapy for esophageal squamous cell carcinoma (ESCC) in Japan, but the prognosis remains poor. We have previously described how definitive chemoradiotherapy with docetaxel, nedaplatin, and 5-fluorouracil (DNF) led to a very high response rate and promising survival times. We therefore undertook a phase II trial to 
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| INTRODUCTION
Esophageal cancer is a highly malignant disease with a poor prognosis. Worldwide, in 2012, 456 000 cases of esophageal cancer were diagnosed, and 400 000 people died from this life-threatening disease. With an overall mortality to incidence ratio as high as 0.88, esophageal cancer is the sixth leading cause of death due to a malignant tumor. 1 Continual improvements have been made in the treatment of advanced esophageal cancer with surgery but these seem to have plateaued, with a 5-year OS rate of 50%-60%. 2 This has led to urgently implementing a multimodality treatment approach, combining chemotherapy, radiotherapy, and surgery. In Europe and North America, NACRT is regarded as standard treatment in response to several studies describing significant improvements in OS by NACRT followed by surgery for esophageal cancer, compared with surgery alone. 2, 3 However, in Japan, such evidence has largely been disregarded, and the use of perioperative chemotherapy has instead been investigated for the treatment of esophageal cancer. 4, 5 This is partly because of differences in the histological type of tumor found, with squamous cell carcinoma more likely to be identified in East Asian countries, whereas adenocarcinoma accounts for about half of esophageal cancer cases in Europe and North America. A disparity in operative procedures, such as the extent of lymphadenectomy, has also led to largely longer PFS in Japan compared to that in other developed nations. Additionally, it is thought that NACRT might increase the likelihood of postoperative complications. 6, 7 From the results of the JCOG9907 study, in which NAC was deemed superior in terms of OS in comparison to adjuvant chemotherapy, esophagectomy following two courses of CDDP plus 5-FU (CF) is regarded as a standard strategy for resectable stage Ib-III ESCC. 5 The rationales for the use of NAC included increasing curability by tumor reduction, and eradicating minimal residual disease that could cause recurrence, among others; failure to achieve a tumor response might result in an inability to undertake curative surgery, or early recurrence after an operation. Therefore, a regimen with strong antitumor activity is needed for NAC. The response rate (RR) for neoadjuvant CF in the JCOG9907 study was limited to 38%; 2.5% of patients were considered to be unresectable because of disease progression. Also, in a subgroup analysis of the study, Esophagectomy with three-field lymphadenectomy (cervical, thoracic, and abdominal) was carried out 4-8 weeks after the completion of the last cycle of DNF. Surgery consisted of right thoracotomy followed by laparotomy and a neck incision with cervical anastomosis.
Thoracoscopic surgery was allowed. Reconstruction was undertaken using a gastric tube or the jejunum through a posterior mediastinal route.
| Assessment and follow-up
Pretreatment assessment included a physical examination, laboratory tests, a chest X-ray, an esophagogastroduodenoscopy, and a An assessment of responses to chemotherapy for measurable lesions was undertaken with CT and/or MRI after each course of chemotherapy according to RECIST guidelines version 1.1. 24 The response of the primary lesion was examined by endoscopy according to the guidelines of the JCEC, 10th edition. 25 An independent review committee confirmed observed responses by radiological and endoscopic examinations. Each patient was assessed every 3 months after surgery for 1 year, then every 6 months for 4 years, and then annually until death.
After surgery, the pathological response of the primary lesion was also evaluated by JCEC according to the proportion of viable tumor cells after chemotherapy as follows: grade 0, no part of tumor affected; grade 1a, less than one-third affected; grade 1b, between one-third and two-thirds affected; grade 2, between two-thirds and entire tumor affected; and grade 3, no viable cancer cells (pCR).
Evaluations of residual tumor (R) were classified by the definition listed in the 7th UICC TNM staging system. 22 Surgical complications were evaluated from the day of surgery until the time of discharge according to the Clavien-Dindo classification and its Japanese extended version.
26,27
| Study design and statistical analysis
The primary end-point was to estimate the completion rate of the protocol treatment. Patients were deemed to have completed the protocol treatment when they received at least two courses of NAC and achieved a pathologically complete resection (R0). Secondary objectives included adverse events, RR including pathological response, PFS, OS, R0 resection rate, and operative morbidity. Given that the expected completion rate was 90% and the threshold incidence was 70%, based on previously reported data in this cohort, 5, 17 with an alpha value of 0.1 (one-sided) and a beta value of 0.1, the required minimum number of patients was 25. The projected sample size was 28 patients in total.
Progression-free survival was defined as the time from the date of registration to that of disease progression or death resulting from any cause, and OS was measured from the date of registration to that of death resulting from any cause. Statistical analyses were undertaken using GraphPad Prism version 7.0d for Mac (GraphPad Subjects. 28 The protocol was approved by the ethics committee of each participating institution.
| RESULTS

| Patient characteristics
Patients' characteristics are summarized in Table 1 . Twenty-eight patients were enrolled from June 2014 to October 2017. The median age was 68.5 years (range, 52-77 years), and most patients were men (85.7%). All patients had an ECOG PS of 0 or 1. Approximately 70% of the patients had a T3/T4a tumor, and more than 80% were clinical stage III. All were assessed for both the presence of any adverse events and their response to treatment.
| Treatment and compliance
The trial profile is shown in Figure 1 . All patients received at least two courses of NAC. Three patients discontinued the third cycle of DNF and proceeded to surgery: two due to patient refusal and one owing to disease progression. A dose reduction in NAC occurred in seven patients in the second cycle and five in the third, mainly because of neutropenia. Seven patients experienced a delay in treatment of 7 days or more, due to protracted neutropenia in five cases and thrombocytopenia in two. Of all 81 treatment cycles in the study, 23 courses were undertaken by patients in an outpatient setting.
In all, 25 patients received subsequent definitive surgery after NAC. Two patients failed to undergo surgery because they were deemed ineligible due to a low forced expiratory volume because of pulmonary emphysema. One refused surgery. These three cases received definitive CRT.
| Toxicity
Adverse events during chemotherapy are listed in Table 2 . Leukocytopenia and neutropenia were major toxicities in 32.1% and 39.3%
of grade 3/4 cases, respectively. Grade 3 febrile neutropenia was observed in 10.7% of patients. Although 10.7% of patients experienced grade 3 thrombocytopenia, grade 4 cases were not observed.
In terms of non-hematological toxicities, grade 4 events were not observed, and grade 3 anorexia, diarrhea, stomatitis, and fatigue were detected at rates of 32.1%, 14.3%, 7.1%, and 3.6%, respectively. Grade 3/4 renal impairment was not observed in any patient.
All events resolved with appropriate care, and treatment-related deaths were not observed. 
| Response
| Survival analysis
With a median follow-up time of 27.2 months, the median PFS was 28.5 months, and 1-/2-year PFS rates were 76.8%/70.4% ( Figure 2A) ; the median survival time was not reached, and 1-/2-year OS rates were 91.6%/77.2% ( Figure 2B ). During follow-up, seven patients presented with locoregional lymph node metastasis, two with distant organ metastasis, and one with both locoregional and distant metastases. Of eight cases who developed lymph node metastases, six involved cervical and superior mediastinal lymph nodes. All seven patients with only locoregional recurrence received definitive CRT, four of whom achieved a CR.
Three cases with distant metastases underwent chemotherapy.
| DISCUSSION
The current standard NAC used in Japan for ESCC is CF. However, the prognosis of patients with this cancer continues to remain poor.
We previously found a high response rate and extended survival times in such patients in response to definitive CRT with DNF. We therefore undertook a phase II trial to evaluate the feasibility and efficacy of neoadjuvant DNF in patients with resectable stage Ib-III ESCC. The treatment completion rate in the current study was 89.3%, with a 95% CI of 77.9%-100%; this study met its primary end-point. To our knowledge, this is the first study to prospectively examine DNF in a neoadjuvant setting. With regard to the dosing method used for DOC, several reports have reported a lower incidence of adverse effects with a weekly dose of DOC compared to a conventional schedule of every 3 weeks. [29] [30] [31] Zimatore et al 31 also observed a higher dose intensity with a weekly schedule of DOC compared with a 3-week administration in a comparative review. In addition, in our previous trial of definitive CRT using DNF, in which a similar schedule was used, few serious toxicities were observed. 21 In contrast, in a phase II study undertaken in Japan examining the 3-week administration of DOC, severe hematological toxicities were observed at an extremely high rate of 88% for grade 3/4 neutropenia and 18% for febrile neutropenia. 8 Because of these observations, we adopted a weekly dosing schedule for DOC in the present study. | 3559 increased hydration. 32 Zhang et al 33 undertook a systematic review comparing CDDP-and CDGP-based chemotherapies for metastatic or recurrent ESCC. They revealed that CDGP was comparable to CDDP in terms of RR and OS, but showed less toxicity in terms of a lower risk of nausea, vomiting, peripheral neuropathy, and nephrotoxicity. The weekly dosing schedule of 50 mg/m 2 CDGP was determined from our previous phase I study of CRT using 5-FU and CDGP. 34 In the same phase I study, this 5-FU was administered in the same way as the current DNF regimen, and its tolerability was shown. 34 In addition, the dose intensity of 5-FU in our trial is equal to that in the JCOG9907 study (800 mg/m 2 /3 weeks), and therefore its safety and efficacy are considered to be verified. 5 Also, we postulate that 5-FU, which induces time-dependent cell growth inhibition, should be administered for a long-time so as to maximize its efficacy.
The schedule we chose for our DNF regimen was based on these observations.
Regarding the dosing frequency of NAC, the JCOG9907 study stipulated two courses of preoperative CF. 5 In comparison, a trial assessing DCF in a neoadjuvant setting reported a high completion rate of 83% for three cycles of DCF. 17 In addition to the above, all patients in our trial of CRT using DNF completed two courses of additional planned chemotherapy after CRT. 21 Meredith et al 35 reported that response and R0 resection rates after NAC correlated with disease-free survival and OS. Based on these results, we specified two to three courses of DNF as the protocol therapy for NAC, after balancing the attributes of strong antitumor activity and feasibility.
Concerning the safety of NAC, the tolerability shown in the study was generally acceptable. The incidence of grade 3/4 neutropenia was found to be 39.3%, which is lower than that observed in studies using a DCF regimen (78.2%-83.3%). 17, 18 Cases with grade 4 thrombocytopenia, a dose-limiting toxicity of CDGP, were not noted. Febrile neutropenia was observed in only 10.7% of patients without grade 4 events. In the current study, prophylactic antibiotics were not allowed, whereas the use of antibiotics for preventive purposes is generally permitted outside of a clinical trial. 36 Therefore, on this basis, we can infer that the incidence of febrile neutropenia will be lower in actual clinical practice. Cases with grade 4 nonhematological toxicity were not noted; patients also did not experience grade 3/4 nephrotoxicity, which is thought to be due to the use of CDGP instead of CDDP. As such adverse events were transient and manageable, it is thought that this favorable safety profile might have contributed to the high completion rate of NAC (two courses, 100%; three courses, 89.3%).
The completion rate for the protocol treatment was high at 89.3%. This was thought to be partly because a high response rate of 87.0% was achieved by DNF, which was higher than not only that reported in JCOG9907 (38%) but also that in trials using DCF (53.7%-64.3%). 5, 7, 18 In addition to using three potent agents, the high completion rate was supported by the low proportion of patients who needed a dose reduction or cessation of treatment; it might also be associated with a high dose intensity, and therefore, efficacy.
Despite a relatively short follow-up period of 27.2 months, the 2-year OS was 77.2%, which is comparable to that observed in trials of DCF. 17, 18 In estimating long-term survival, the high R0 resection rate of 100% for patients who underwent surgery in the current study is particularly meaningful. For example, Gertler et al 37 analyzed
the prognoses of 2920 resected cases with esophageal cancer and revealed that an R0 resection was an independent prognostic factor.
Others reached the same conclusion in a reproducible manner, so the significance of an R0 resection as a prognostic factor is thought to be well established. 38, 39 As with an R0 resection, it is noteworthy that the pCR rate was 32.0%, which is markedly superior to that obtained by CF (5%) and DCF (12%-17%). 5, 17, 18 The importance of a pCR as a prognostic factor has been pointed out in previous reports. 40, 41 Furthermore, Tomasello et al 42 reported a meta-analysis of 17 studies with 3145 cases who received neoadjuvant therapy, F I G U R E 2 Kaplan-Meier curves of progression-free survival (A) and overall survival (B) in Japanese patients with resectable esophageal squamous cell carcinoma treated with docetaxel, nedaplatin, and 5-fluorouracil. The estimated 1-year progression-free and overall survival rates were 76.8% and 91.6%, respectively and found that a pathologic response was strongly associated with a significant improvement in OS.
The rate of postoperative complications was found to be low, with an incidence of 28%, with most events not considered severe.
In addition, mortality related to surgery was not noted. In particular, pneumonia, a major complication in surgery for esophageal can- 44, 45 Although few studies have reported the incidence of surgical morbidity, in two trials using DCF for NAC this was
shown to be 32%-39% and included pneumonia. In these studies, the proportion of patients who received thoracoscopic surgery was less than 5%. 16, 46 Progression-free survival in our study was almost identical to that observed in a trial using DCF. 17 In conclusion, we have shown that combination chemotherapy with DNF is a promising preoperative regimen for resectable ESCC,
showing an acceptable feasibility with a completion rate for protocol treatment of 89.3%, and strong antitumor efficacy. These results were quite promising, but the existence of several limitations of our investigation must be acknowledged, including the single-armed nature of the study, and the relatively small number of patients recruited. Additional trials with larger cohorts and longer follow-up periods are needed to confirm the findings of the current study. 
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